# Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

> **NCT00393991** · PHASE3 · COMPLETED · sponsor: **SkyePharma AG** · enrollment: 475 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone propionate/formoterol fumarate 100/10
- **DRUG:** Fluticasone propionate 100
- **DRUG:** Formoterol fumarate 10
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00393991
- **Lead sponsor:** SkyePharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 475 (ACTUAL)
- **Last updated:** 2011-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00393991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00393991, "Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00393991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*